



February 13, 2026

To
The Manager
Corporate Relations Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001

Scrip Code - 524506

Dear Sir/Madam,

Subject: Outcome of the Board Meeting held on February 13, 2026, pursuant to Regulation 30 (Read with Part A of Schedule III) the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable provisions, the Board of Directors of the Company in its meeting held on Friday, February 13, 2026 at the Corporate Office of the Company situated at 3B, Patanwala Compound, Opp. Shreyas Cinema, L.B.S. Marg, Ghatkopar (W), Mumbai-400086, has inter alia considered and approved:

1. the Unaudited Standalone Financial Results for the quarter and nine months ended on December 31, 2025 and Limited Review Report submitted by M/s S. C. Mehra & Associates LLP, Statutory Auditor of the Company thereon in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The results will be uploaded on the Company's website <http://www.corallab.com> will be published in newspapers as per Regulation 30 & 47 under SEBI (Listing Obligation and Disclosure Requirements), Regulations 2015.

This is for your information and records.

The Meeting commenced at 12:15 p.m. and was concluded by 15:35 p.m. on the same day.

Yours sincerely,

For Coral Laboratories Limited

Sushma Kadkade
Director & CFO
DIN: 07791735

Place: Mumbai



CORAL LABORATORIES LTD

AN ISO 9001: 2008 CERTIFIED ORGANIZATION



REGD. OFFICE : #3B, Patanwala Compound, Opp. Shreyas Cinema, L.B.S. Marg, Ghatkopar (West), Mumbai - 400 086. India
 Tel. : +91-22-2500 5245, 2500 8208, 2500 5246. • Fax : +91-22-2500 4893. • E-mail : accounts@corallab.com • Website : www.corallab.com
 CIN NO. L24231MH1997PLC422233

Statement of Standalone Unaudited Financial Results for Nine Month ended 31st Dec 2025

(Rs. in Lakhs) (Except Figures in EPS)

Sr. No	Particulars (Refer Notes Below)	Quarter Ended			Nine Month Ended		Year Ended
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
1	Income						
	(a) Revenue from Operations	2156.42	1903.48	2298.61	5942.04	8687.06	11500.53
	(b) Other Income	249.30	270.87	252.30	724.98	662.73	910.86
2	Total income	2405.72	2174.35	2550.91	6667.03	9349.79	12411.39
3	Expenses						
	(a) Cost of Materials consumed	1293.10	730.61	898.16	2857.02	3675.16	4814.32
	(b) Purchase of stock-in-trade	75.06	80.97	16.08	237.92	113.61	156.15
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-500.00	-56.54	32.30	-598.00	56.12	331.50
	(d) Employee benefits expense	440.20	369.93	338.40	1152.26	1090.52	1473.71
	(e) Depreciation and amortisation expense	68.69	45.22	50.15	159.49	150.45	201.06
	(f) Financial Cost	0.08	10.27	1.93	16.13	5.90	9.76
	(g) Other expenses	659.03	284.62	382.44	1391.71	1396.19	2100.91
	Total Expenses	2036.16	1465.09	1719.46	5216.54	6487.93	9087.41
4	Profit from operations before exceptional items and tax	369.55	709.27	831.45	1450.49	2861.86	3323.98
5	Exceptional Items (Provision of Income tax of earlier year)	0.00	-32.25	0.00	-32.25	0.00	76.96
6	Profit from ordinary activities before tax	369.55	741.51	831.45	1482.74	2861.86	3247.02
7	Tax expense						
	(a) Current Tax	90.00	159.00	215.00	364.00	723.00	833.00
	(b) Deferred Tax	2.00	0.50	2.00	3.00	6.00	-1.54
8	Profit from Continuing Operation	277.55	582.01	614.45	1115.74	2132.86	2415.56
9	Profit From discontinuing operations						
10	Profit for the period	277.55	582.01	614.45	1115.74	2132.86	2415.56
11	Other Comprehensive Income						
A	i) Items that will not be reclassified to profit and loss	-201.53	-212.85	125.33	148.77	1283.44	26.80
	ii) Income tax relating to income that will not be reclassified to profit and loss	-	-	-	-	-	-
12	Total Comprehensive income for the period (Comprising profit and loss and other Comprehensive Income for the period)	76.02	369.16	739.78	1264.51	3416.30	2442.37
13	Paid up Equity Share Capital (Face Value Rupees 10 per share)	357.26	357.26	357.26	357.26	357.26	357.26
14	Reserve excluding Revaluation reserve as per balance sheet of the previous accounting year	0.00	0.00	0.00	0.00	0.00	19763.32
15	i) Earnings Per Share (before extraordinary items)						
	(of Rs.10/- each):						
	(a) Basic	7.77	16.29	17.20	31.23	59.70	67.61
	(b) Diluted	7.77	16.29	17.20	31.23	59.70	67.61
	ii) Earnings Per Share (after extraordinary items)						
	(of Rs.10/- each) :						
	(a) Basic	7.77	16.29	17.20	31.23	59.70	67.61
	(b) Diluted	7.77	16.29	17.20	31.23	59.70	67.61

For Coral Laboratories Limited

Sushma Kaddade
 Sushma Kaddade
 Director & CFO
 DIN : 07791735



Prakash M. Dhameja
 Prakash M. Dhameja
 Whole Time Director
 DIN : 07798455



CORAL LABORATORIES LTD

AN ISO 9001: 2008 CERTIFIED ORGANIZATION



REGD. OFFICE : #3B, Patanwala Compound, Opp. Shreyas Cinema, L.B.S. Marg, Ghatkopar (West), Mumbai - 400 086. India
Tel. : +91-22-2500 5245, 2500 8208, 2500 5246. • Fax : +91-22-2500 4893. • E-mail : accounts@corallab.com • Website : www.corallab.com
CIN NO. L24231MH1997PLC422233

Notes:

- 1 The Unaudited Standalone Financial Results for the quarter and Nine months ended December 31, 2025 have been reviewed by the Audit Committee and were approved by the Board of Directors of the Company at their respective meetings held on **February 13, 2026**
- 2 This statement is as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These audited financial results of the Company were prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ('IND AS') and other accounting principles generally accepted in India and guidelines issued by the Securities Exchange Board of India ("SEBI").
- 3 The Statutory Auditors have carried out the Limited Review of the financial results of the Company.
- 4 The Company has only one segment viz. "Formulations" as per Indian Accounting Standard 108 of ICAI.
- 5 During the quarter and Nine months ended December 31, 2025, the Company do not have any subsidiary/associate/joint venture company(ies).
- 6 Corresponding quarter/year figures have been regrouped/reclassified wherever necessary to confirm to the classification of the current period.

For Coral Laboratories Limited


Sushma Kadkade
Director & CFO
DIN : 07791735


Girish M. Dhameja
Whole Time Director
DIN : 07798455



Place : Mumbai

Date : Feb 13, 2026

Independent Auditor's Review Report on Unaudited Quarterly Standalone Financial Results of the Company, pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors
Coral Laboratories Limited

1. We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **CORAL LABORATORIES LIMITED** ("the Company"), for the quarter ended December 31, 2025, ("the statement") being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the Indian Accounting Standard 34 "Interim Financial reporting" ("Ind AS 34") as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S C Mehra & Associates LLP
Chartered Accountants
(FRN No. 106156W/W100305)



CA Suresh Mehra
Partner
M.No. 039730



Place: Mumbai
Date: 13-02-2026

UDIN: 26039730TGTHTP3430

S C MEHRA & ASSOCIATES LLP

Head Office: Office No. 42, 1st Floor, Singh Estate No. 3, Near Mrinaltai Gore Flyover, Next to D'Mart, Ram Mandir (West),
Mumbai - 400 104, Maharashtra, India.
Mob. : +91 9820060260 • Email: sc.mehra@scmassociates.in
Branches: Ahmedabad • Bengaluru • Bhopal • Delhi NCR • Hyderabad • Jaipur • Jodhpur • Thane